Drug intelligence / Profile preview

arsenic trioxide + ascorbic acid

Development stage: Unknown
Lead developer: Jacobson Pharma
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Arsenic trioxide (ATO) combined with ascorbic acid is a therapeutic combination primarily used in the treatment of acute promyelocytic leukemia (APL). Ascorbic acid appears to enhance the efficacy of ATO while potentially reducing its toxicity. This combination is often part of the "AAA regimen" when combined with all-trans retinoic acid (ATRA). The combination can be administered orally or intravenously and has shown significant efficacy in both newly diagnosed and relapsed APL cases.

Other names: ATO + ascorbic acidAAA regimen component

Targets

PML-RARA (PML-retinoic acid receptor alpha fusion protein)

Beyond the preview

Go deeper on arsenic trioxide + ascorbic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on arsenic trioxide + ascorbic acid.

Explore the full profile